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introduction: Whether, new oral anticoagulants (NOACs) are alternative to warfarin for extended treatment of venous thromboembolism (VTE) is 
not clear. We performed a meta-analysis of all randomized controlled trials (RCTs) to assess the safety and efficacy of NOACs for long-term treatment 
of VTE.
methods: We searched PubMed, Cochrane library and Embase for RCTs comparing NOACs (dabigatran, apixaban, rivaroxaban, and edoxaban) 
with placebo or warfarin for long-term treatment of VTE. Outcomes studied were recurrent VTE or VTE-related death and major or clinically relevant 
bleeding (MB). Random effects model was used for statistical analyses.
results: We identified 5 RCTs (n=16117) which compared NOACs (n=8484) with either placebo (n=2085) or warfarin (n=5548). NOACs 
significantly reduced the risk of VTE or VTE-related death when compared to placebo/ warfarin (OR: 0.33; 95% CI, 0.13 -0.87). However, subgroup 
analysis did not reveal any significant difference between NOACs and warfarin (OR: 1.03; 95% CI, 0.60 -1.77). Compared to placebo, NOACs 
increased the risk of bleeding (OR: 2.69; 95% CI, 1.26 -5.75). However, there was a trend towards decreased MB when compared to warfarin (OR: 
0.66; 0.43 - 1.01).
conclusions: NOACs are effective for the long term treatment of VTE with reduced risk of VTE or VTE related deaths compared with placebo but 
similar efficacy to warfarin.
